Medtronic Agrees to Buy Contego Medical to Boost Stroke Prevention Tools
Minneapolis, Monday, 16 November 2026.
Medtronic plans to acquire Contego Medical for $380 million, securing an FDA-approved carotid therapy that achieved zero strokes and zero heart attacks at 30 days in clinical trials.
A Strategic Expansion in Stroke Prevention
Medtronic plc (NYSE: MDT), a global leader in medical technology, has announced its agreement to acquire Contego Medical in a deal valued at $380 million, including potential post-acquisition payments [1][2][3][4][5][6][7][8]. The acquisition is designed to significantly enhance Medtronic’s portfolio of stroke prevention tools by integrating Contego’s pioneering technologies for carotid artery disease and peripheral vascular interventions [1][2][3][4][5][6][7][8]. The agreement was confirmed on Monday, 16 November 2026, marking a pivotal step in Medtronic’s strategy to strengthen its leadership in neurovascular and peripheral vascular therapies [1][2][3][4][5][6][7][8].
The Clinical Breakthrough Behind the Deal
At the heart of this acquisition is Contego Medical’s Neuroguard IEP Direct System, a transcarotid artery revascularization (TCAR) system that integrates embolic protection and flow reversal mechanisms [1][2][4][5][6][7][8][9]. The system is the first of its kind to combine these features, and its efficacy has been validated in clinical studies. According to the PERFORMANCE III study, the Neuroguard IEP Direct System achieved zero strokes, zero neurological deaths, zero cranial nerve injuries, and zero myocardial infarctions at 30 days among evaluated participants [1][2][4][5][6][7][8]. These clinical outcomes underscore the system’s potential to redefine standards in carotid revascularization procedures, particularly in reducing the risk of embolic events during treatment [1][2][4][5][6][7][8].
Contego’s Portfolio Complements Medtronic’s Core Offerings
Contego Medical’s portfolio extends beyond the Neuroguard IEP Direct System to include the Excipio thrombectomy devices, which are designed to address peripheral vascular disease by removing blood clots obstructing circulation [3][4][5][7][8]. These devices complement Medtronic’s existing Liberant thrombectomy system, thereby expanding the company’s capabilities in treating a broader range of vascular conditions [3][4][5][7][8]. The acquisition also builds on an exclusive U.S. distribution agreement that Medtronic and Contego Medical established in January 2025, a relationship that has now transitioned into full ownership [1][2][3][4][5][6][7][8].
Financial and Strategic Implications
Medtronic expects the acquisition to close in the third quarter of its fiscal year 2027, subject to customary closing conditions [1][2][3][4][5][6][7][8]. The transaction is projected to be minimally dilutive to Medtronic’s adjusted earnings per share (EPS) in fiscal years 2027 and 2028, with the potential to become neutral to accretive in subsequent periods [1][2][3][4][5][6][7][8]. This financial outlook reflects Medtronic’s confidence in the long-term value of integrating Contego’s technologies into its cardiovascular division, which currently accounts for 17.8% of the company’s net sales by activity [1]. The acquisition is part of a broader strategy to pursue targeted investments that deepen Medtronic’s core franchises rather than venturing into entirely new markets [5][6][7][8].
Expert Reactions and Market Response
David Moeller, Senior Vice President and President of Medtronic Peripheral Vascular Health, emphasized the strategic importance of the acquisition: ‘With this acquisition, Medtronic is taking another important step to strengthen our leadership in the treatment of carotid artery disease. By pairing Medtronic’s deep clinical expertise in peripheral and neurovascular technologies with Contego’s next-generation treatments backed by strong and consistent clinical data, we intend to become an undisputed leader in carotid revascularization’ [2][7][8]. Ravish Sachar, Founder and CEO of Contego Medical, echoed this sentiment, noting that the acquisition represents an exciting next chapter for the company: ‘Contego was founded to address unmet needs in clinical practice by developing technologies designed to improve outcomes while simultaneously simplifying procedures’ [2][7][8]. Linnea Burman, Senior Vice President and President of Medtronic Neurovascular, highlighted the broader societal impact of the deal, stating: ‘Stroke-related disability underscores the need for more innovative treatment options — and the opportunity to make a meaningful difference for patients’ [2][7][8]. On the day of the announcement, Medtronic’s shares rose 0.62% to $103.50 in overnight trading, reflecting positive investor sentiment [9].
Timeline and Future Outlook
The acquisition timeline is clear: Medtronic announced its intent to acquire Contego Medical on Sunday, 15 November 2026, with the deal formally announced on Monday, 16 November 2026 [1][2][4][5][6][7][8]. The closing is anticipated in the third quarter of Medtronic’s fiscal year 2027, which began on 25 April 2026 [1][2][3][4][5][6][7][8]. While the immediate financial impact is expected to be minimally dilutive to adjusted EPS, Medtronic anticipates that the acquisition will contribute positively to its long-term growth trajectory by enhancing its carotid and peripheral vascular portfolios [1][2][3][4][5][6][7][8].
Sources
- ca.marketscreener.com
- news.medtronic.com
- evtoday.com
- dealroom.co
- www.morningstar.com
- pulse2.com
- www.rttnews.com
- pluang.com